(19)
(11) EP 3 912 643 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.08.2023 Bulletin 2023/34

(45) Mention of the grant of the patent:
05.10.2022 Bulletin 2022/40

(21) Application number: 21176545.8

(22) Date of filing: 02.12.2009
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 2039/505; C07K 16/1063; C07K 16/2803; C07K 16/2833; C07K 16/2863; C07K 16/30; A61K 47/6889; A61K 47/6841; A61K 47/6849; A61K 47/6853; A61K 31/4745; A61K 45/06; A61K 47/6803; C07D 491/22; A61K 47/6851; A61P 17/00; A61P 29/00; A61P 31/00; A61P 31/04; A61P 31/12; A61P 31/18; A61P 35/00; A61P 35/04; A61P 37/02; A61P 37/06; Y02A 50/30; A61K 47/6859

(54)

IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE

IMMUNKONJUGATE MIT EINER INTRAZELLULÄR SPALTBAREN KOPPLUNG

IMMUNOCONJUGUÉS COMPORTANT UNE LIAISON INTRACELLULAIRE CLIVABLE


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 13.02.2009 US 207890 P

(43) Date of publication of application:
24.11.2021 Bulletin 2021/47

(62) Application number of the earlier application in accordance with Art. 76 EPC:
18200201.4 / 3470087
17178086.9 / 3243527
09840166.4 / 2396036

(73) Proprietor: Immunomedics, Inc.
Morris Plains, NJ 07950 (US)

(72) Inventors:
  • GOVINDAN, Serengulam
    Morris Plains, 07950 (US)
  • MOON, Sung-Ju
    Morris Plains, 07950 (US)
  • GOLDENBERG, David M
    Morris Plains, 07950 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A1-2004/054622
WO-A2-2008/088658
WO-A2-2007/112193
US-A1- 2008 166 363
   
  • SUNG-JU MOON ET AL: "Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 21, 22 October 2008 (2008-10-22), pages 6916-6926, XP055044282, ISSN: 0022-2623, DOI: 10.1021/jm800719t
  • T. M. CARDILLO ET AL: "Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys", CLINICAL CANCER RESEARCH, vol. 17, no. 10, 3 March 2011 (2011-03-03) , pages 3157-3169, XP055398728, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2939
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).